AZ bets big on biologics with $285M Swedish facility

AstraZeneca ($AZN), trying to turn its sales performance around, has some biologics launches on the horizon. But to accommodate them, it needs more manufacturing capacity, and it thinks a new $285 million plant in Sweden will do the trick. More from FiercePharma